From The Stage

Supporting Biosimilar Assessment: Best Practices for the Development and Validation of Neutralizing Antibody Assays

Posted by / / Biosimilars, Immunogenicity

Immunogenicity assessments are a critical component to determining the comparability of an originator drug and a biosimilar. It is necessary to determine both neutralizing and non-neutralizing antibody incidence for an originator drug and a biosimilar, and understand the immunogenicity’s impact on PK results as well as its association with adverse events.

Strategic Bioanalytical Partnerships for the Win-Win-Win

Posted by / / Cell-Based Assays, CRO Selection

For bioanalytical CROs, it is of critical importance to build an internal team capable of meeting their pharmaceutical and biotech customers’ drug development goals. However, many overlook the benefits of strategically aligning with external partners – those organizations that can add value to the CRO’s offerings, supplementing their solutions and services to make them more comprehensive and attractive to customers.

BioAgilytix Team Q&A: Meet Matt Bray, Scientist and Bioanalytical Project Manager

Posted by / / BioAgilytix Insight, CRO Selection

To gain a better understanding of how BioAgilytix delivers its premium bioanalytical services, it is important to know the people that drive our science. In this Q&A session, we get to know Matt Bray, Scientist/Bioanalytical Project Manager (BPM) at BioAgilytix, and how he has grown with the company since starting as our very first analyst nearly 8 years ago.